Stockscreener 앱 받기
23.37
2.82%
0.64
Alumis Inc 주식(ALMS)의 최신 뉴스
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Yahoo Finance
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Yahoo Finance
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - Stock Titan
Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - Stock Titan
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - Stock Titan
Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - Stock Titan
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans - sahmcapital.com
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why Alumis Inc. Shares Are Suddenly Surging - tipranks.com
HC Wainwright Brokers Raise Earnings Estimates for Alumis - MarketBeat
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - The Globe and Mail
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases - biospace.com
FY2027 Earnings Estimate for Alumis Issued By HC Wainwright - marketbeat.com
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data - Citeline News & Insights
Oppenheimer Raises Price Target for ALMS, Maintains Outperform R - GuruFocus
Alumis (ALMS): HC Wainwright & Co. Lowers Price Target, Maintains Buy Rating | ALMS Stock News - GuruFocus
Alumis (ALMS) Maintains "Buy" Rating and Price Target by Chardan Capital | ALMS Stock News - GuruFocus
Why is Alumis stock falling Monday? - MSN
Alumis price target raised to $55 from $50 at Oppenheimer - tipranks.com
Why Is Alumis Stock Falling Monday?Alumis (NASDAQ:ALMS) - Benzinga
Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade - MarketBeat
Leerink reiterates Alumis stock rating on consistent trial data - Investing.com UK
US Stocks Recap: Is Alumis Incs growth already priced inTrade Exit Report & Verified Short-Term Plans - baoquankhu1.vn
Leerink reiterates Alumis stock rating on consistent trial data By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Alumis stock after trial data By Investing.com - Investing.com South Africa
Raymond James reiterates Strong Buy on Alumis stock after trial data - Investing.com India
Alumis (NASDAQ:ALMS) Given New $55.00 Price Target at Oppenheimer - MarketBeat
Guggenheim reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Baird reiterates Alumis stock rating on Phase 3 data strength - Investing.com
Guggenheim reiterates Alumis stock rating on psoriasis trial data - Investing.com
Expedia To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Envudeucitinib Shows Early, Robust Skin Clearance and Quality of Life Improvements in Phase 3 Plaque Psoriasis Trials by Alumis Inc. 123 - minichart.com.sg
Oppenheimer Adjusts Alumis Price Target to $55 From $50, Maintains Outperform Rating - MarketScreener
Alumis stock price target lowered to $25 by H.C. Wainwright on competitive pressures - Investing.com India
Stifel reiterates Alumis stock Buy rating after psoriasis data By Investing.com - Investing.com Canada
Chardan Capital Reiterates "Buy" Rating for Alumis (NASDAQ:ALMS) - MarketBeat
Stifel reiterates Alumis stock Buy rating after psoriasis data - Investing.com
HC Wainwright Cuts Alumis (NASDAQ:ALMS) Price Target to $25.00 - MarketBeat
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib - tipranks.com
Alumis Inc. Soars On Breakthrough Psoriasis Drug Update - tipranks.com
Alumis: Envudeucitinib Shows Robust PASI 90/100 Responses and QoL Gains in Phase 3 ONWARD Trials - TradingView
Phase 3 win positions Alumis (NASDAQ: ALMS) psoriasis pill for 2026 NDA - Stock Titan
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout - MarketBeat
Alumis (ALMS) Confronts Potential Regulatory Reassessment with NDA Submission Expected in Second Half of 2026 - Bitget
A Look At Alumis (ALMS) Valuation After ONWARD Phase 3 Psoriasis Data And FDA Filing Plans - simplywall.st
Alumis reports Phase 3 psoriasis trial results for envudeucitinib By Investing.com - Investing.com South Africa
Alumis’ Envudeucitinib Meets Co-Primary Endpoints in ONWARD1 and ONWARD2 Phase 3 Trials - Dermatology Times
Alumis reports Phase 3 psoriasis trial results for envudeucitinib - Investing.com
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis - manilatimes.net
0.49%
1.47%
자본화:
|
볼륨(24시간):